

Jianqing Xu, M.D &PhD, Professor at Fudan University.

Dr. Jianqing Xu is a member of International Society of Analytical Cytology (ISAC), a member of Microbiology and Immunology Council in China. He has been working on HIV vaccine development and HIV immunology for over a decade and established a HIV-specific T-cell assay base on inactivated HIV particles, developed a therapeutic vaccine named as DermaVir which is under the clinical testing both in Europe and USA. In addition, he proposed a new vaccine strategy “Sequential Immunization with Heterologous Immunogens” which is capable of preferentially stimulating immunity against HIV conserved subdominant epitopes, such a strategy may be also applicable for HCV and influenza. Currently, his team focuses on novel strategies to develop effective vaccines against HIV-1 and influenza and to explore the immune protective mechanism in HIV-1 infection.

Selected Publications (*correspondence author)

1. Wan Y, **Xu J***. HIV/AIDS vaccine development: Are we walking out from the darkness? *Chinese Medical Journal* (Engl), 2010, 123: 3489-94.
2. Somogyi E, **Xu J**, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP(+)) mimicking naturally occurring HIV. *Vaccine*. 2010 Nov 23.
3. MENG Zhe-feng, ZHANG Xiao-yan, XIN Ruo-lei, XING Hui, HE Xiang, **Xu J*** and SHAO Yi-ming. A new approach for sequencing virion genome of Chinese HIV-1 strains subtype B and BC from plasma. *Chin Med J* [IF: 0.952] 2011, 124(2):304-308.
4. Yao X, Wang X, Zhao C, Sun S, Meng Z, Zhang J, **Xu J**, Xie Y, Yuan Z and Wen Y. Transcriptional Analysis of Immune-Related Genes in Dendritic Cells From Hepatitis B Surface Antigen (HBsAg)-Positive Transgenic Mice and Regulation of Fc Gamma Receptor IIB by HBsAg-Anti-HBs Complex. *Journal of Medical Virology*, 2011; 83:78 - 87.
5. Meng Z, Hu H, Zhang X, Lv J, **Xu J***. New Circulating CRF07_BC Forms with 7 Amino Acid Deletion in gag p6 and Characterization of Its Molecular clones. *Virology Journal*, 2011, 8: 60.
6. Wang W, **Xu J (co-first author)**, Jiang S, Yang K, Meng Z, Ma Y, Li M, Zhang X, Zhang F, Shao Y and Zhang X. The dynamic face of HIV-1 subtypes among men who have sex with men in China. *Current HIV Research*. 2011, 9: 136-139.
7. Congyou Zhang; Yanmin Wan; Jijing Shi; Mingzhe Zhou; Zhefeng Meng; Songhua Yuan; Chao Qiu; Xiaoyan Zhang; Xuemei Xu; Chaoqi Liu, **Jianqing Xu***. Deglycosylation of HIV-1 AE Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies against Heterologous HIV-1 Clade. *AIDS Research*

and Human Retroviruses, 2010; 26: 569-75..

8. Yong Qiao, Yang Huang, Chao Qiu, Xinye Yue, Liandong Deng, Yanmin Wan, Jinfeng Xing, Congyou Zhang, Songhua Yuan, Anjie Dong, **Jianqing Xu***. The Use of PEGylated Poly [2-(N, N-dimethylamino) ethyl methacrylate] as A Mucosal DNA Delivery Vector and the Activation of Innate Immunity and Improvement of HIV-1-specific Immune Responses. **Biomaterials**, 31 (2010): 115 - 123
9. Yang Huang, Chao Qiu, Hong Peng, Lianxing Liu, Yanmeng Feng, Ting Zhu, Chao Wu, **Jianqing Xu***. A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine. **Chinese Medical Journal (Engl)**, 2009, 122 (14):1655-1659.
10. Yanmin Wan, Lianxing Liu, Lan Wu, Xianggang Huang, Chao Qiu, Liying Ma and **Jianqing Xu***. Deglycosylation or Partial Removal of HIV-1 CN54 gp140 V1/V2 Domain Enhance Specific T-cell but not humoral Immunity. **AIDS Research and Human Retroviruses**, 2009, 25(6):607-17.
11. Xiaoyan Zhang, **Jianqing Xu** (Co-first author), Hong Peng, Yan Ma, Lifeng Han, Yuhua Ruan, Bing Su, Ning Wang, Yiming Shao. HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naïve to ART. **Plos One** 2008, 3(12): e3992.
12. Dai K, Liu Y, Liu M, **Jianqing Xu**, Huang W, Huang X, Liu L, Wan Y, Hao Y, Shao Y. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. **Vaccine**, 2008, 26: 5062-71
13. QIU Chao, **XU Jianqing***. HIV/AIDS vaccine development: Are we in the darkness before the dawn? **Chinese Medical Journal (Engl)**, 2008, 121: 939-45. [Invited review]
14. Ruijun Zhang, **Jianqing Xu**, Kunxue Hong, Lin Yuan, Hong Peng, Pengfei Ma, Yuanzhi Zhang, Hui Xing, Yuhua Ruan, and Yiming Shao. NKG2A progressively increased in cytotoxic NK subset with the disease progression in HIV-1 infected individuals. **AIDS**, 2007, 21 (Suppl): s9-17.
15. Xianggang Huang, Lianxing Liu, Li Ren, Chao Qiu, Yanmin Wan and **Jianqing Xu***. Mucosal Priming with Replicative Tiantan Vaccinia and Systemic Boosting with DNA Vaccine Raised Strong Mucosal and Systemic HIV-specific Immune Responses. **Vaccine**. 2007, 25(52): 8874-84.
16. Lianxing Liu, Yanmin Wan, **Jianqing Xu***, Xianggang Huang, Lan Wu, Yong Liu, Yiming Shao. Immunogenicity Comparison between Codon Optimized HIV-1 CRF BC_07 gp140 and gp145 Vaccines. **AIDS Research and Human Retrovirus**, 2007, 23 (11): 1396-1404.
17. Yanmin Wan, Lan Wu, Lianxing Liu, **Jianqing Xu**, Ying Liu, Yong Liu and Yiming Shao. Comparison of Immunogenicity between Codon Optimized HIV-1 Thailand Subtype B gp140 and gp145 Vaccines. **Vaccine**, 2007, 25: 4949-4959.
18. Xianggang Huang, **Jianqing Xu***, Chao Qiu, Li Ren, Lianxing Liu, Yanmin Wan, Ning Zhang, Hong Peng & Yiming Shao. Mucosal Priming with PEI/DNA Complex and Systemic Boosting with Recombinant TianTan Vaccinia Stimulate Vigorous Mucosal

- and Systemic Immune Responses. *Vaccine*, 2007, 25:2620-9.
19. **Jianqing Xu***, Li Ren, Xianggang Huang, Chao Qiu, Yong Liu, Ying Liu, Yiming Shao. Sequential Priming and Boosting with Heterologous HIV Immunogens Predominantly Stimulated T-cell Immunity against Conserved Epitopes. *AIDS*, 2006, 20: 2293-2303.
 20. Lisziewicz J, Trocio J, Whitman L, Varga G, **Jianqing Xu**, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. Dermavir: A Novel Topical Vaccine for HIV/AIDS. *J. Investigative. Derm.* 2005, 124:160-9.
 21. Lisziewicz J, Trocio J, **Jianqing Xu**, Whitman L, Ryder A, Bakare N, Lewis M, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with DermaVir. *AIDS*, 2005, 19: 35-43.
 22. **Jianqing Xu**, Lori F, Lisziewicz J. Vaccinia assay for the rapid detection of functional HIV-specific CD8⁺ cytotoxic T lymphocytes. *Journal of Immunological Methods*, 2003, 276: 45-57.
 23. **Jianqing Xu**, Whitman L, Lori F, Lisziewicz J. Quantification of HIV-specific CD8⁺ T Cells by *in vitro* stimulation with inactivated viral particles. *AIDS*, 2002, 16: 1849-1857.
 24. **Jianqing Xu**, Whitman L, Lori F, Lisziewicz J. Methods of using IL-2 to enhance HIV-specific immune responses. *AIDS Research and Human Retrovirus*, 2002, 18: 289-293.
 25. Lisziewicz J, Gabrilovich D, Varga G, **Jianqing Xu**, Greenberg P, Arya S, Bosch M, Behr J. & Lori, F. Induction of potent HIV-1-specific T cell restricted immunity by genetically modified dendritic cells. *J. of Virology*, 2001, 75: 7621-8.
 26. Lori F, Lewis M, **Jianqing Xu**, Varga G, Zinn D, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C & Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection. *Science*, 2000, 290: 1591~93.